Adamas Pharmaceuticals, Inc.

200 articles about Adamas Pharmaceuticals, Inc.

• Adamas Reports Second Quarter 2020 Financial Results

  8/6/2020

  Second quarter 2020 GOCOVRI® product sales of $18.0 million, a 41% increase over second quarter 2019

• Adamas to Announce Second Quarter 2020 Financial Results and Host Conference Call on August 6, 2020

  7/23/2020

  Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2020 second quarter financial results on Thursday, August 6, 2020, after market close.

• Adamas presents new post-hoc Phase 3 data analysis for GOCOVRI® in Parkinson’s disease at the 2020 American Academy of Neurology (AAN) Science Highlights Platform

  7/15/2020

  Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced its presentation of a new post-hoc pivotal trial data analysis at the American Academy of Neurology (AAN) Science Highlights Platform showing GOCOVRI decreasing dyskinesia and OFF time for people with Parkinson’s Disease (PD) using GOCOVRI® (aman

• Adamas Announces New Employment Inducement Grant - July 10, 2020

  7/10/2020

  Adamas Pharmaceuticals, Inc. announced that the compensation committee of the company’s board of directors granted three new employees the option to purchase an aggregate of 62,500 shares of the company’s common stock, at a per share exercise price of $2.57, the closing trading price on July 8, and restricted stock units to acquire 31,250 shares of the company’s common stock.

• Adamas provides program update for ADS-5102 for multiple sclerosis patients with walking impairment

  6/17/2020

  Adamas Pharmaceuticals, Inc., a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, announced the completion of its evaluation of ADS-5102 in multiple sclerosis patients with walking impairment.

• Adamas announces FDA filing acceptance of sNDA to modify the indication statement for GOCOVRI® to include treatment for Parkinson’s disease patients receiving levodopa and experiencing OFF episodes

  6/4/2020

  Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), today announced that its supplemental New Drug Application (sNDA) for GOCOVRI as a treatment for OFF episodes in Parkinson’s disease (PD) patients receiving levodopa-based therapy has been accepted for review by the U.S. Food and Drug Administration (FDA)

• Adamas to Present at Upcoming William Blair Conference

  6/3/2020

  Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the Company’s Chief Executive Officer, is scheduled to present at the William Blair Growth Stock Conference on Wednesday,

• Adamas announces issuance of new U.S. patent for GOCOVRI in Parkinson’s disease - expands coverage with reduction of ‘OFF’ time and increased ‘good ON’ time

  5/13/2020

  Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has been issued a new patent (no. 10,646,456) by the United States Patent and Trademark Office (USPTO) that covers GOCOVRI ® (amantadine) extended release capsules. The new patent covers a method of reducing ‘OFF’ time and increasing ‘good ON

• Adamas Announces New Employment Inducement Grant - May 08, 2020

  5/8/2020

  Adamas Pharmaceuticals,. today announced that the compensation committee of the company’s board of directors granted five new employees the option to purchase an aggregate of 66,000 shares of the company’s common stock, at a per share exercise price of $3.46, the closing trading price on May 7, and restricted stock units to acquire 33,000 shares of the company’s common stock.

• Adamas Reports First Quarter 2020 Financial Results

  5/7/2020

  Adamas Pharmaceuticals, Inc., a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, reported financial results for the first quarter ended March 31, 2020, as well as recent corporate highlights.

• Adamas to Announce First Quarter 2020 Financial Results and Host Conference Call on May 7, 2020

  4/27/2020

  Adamas Pharmaceuticals, Inc. announced that the company will report 2020 first quarter financial results on Thursday, May 7, 2020, after market close.

• Adamas Announces New Employment Inducement Grant - April 10, 2020

  4/10/2020

  Adamas Pharmaceuticals, Inc. announced that the compensation committee of the company’s board of directors granted seven new employees the option to purchase an aggregate of 86,000 shares of the company’s common stock, at a per share exercise price of $2.84, the closing trading price on April 7, and restricted stock units to acquire 43,000 shares of the company’s common stock.

• Adamas Announces New Employment Inducement Grant - March 06, 2020

  3/6/2020

  Adamas Pharmaceuticals, Inc. announced that the compensation committee of the company’s board of directors granted six new employees the option to purchase an aggregate of 70,000 shares of the company’s common stock, at a per share exercise price of $3.89, the closing trading price on March 6, and restricted stock units to acquire 35,000 shares of the company’s common stock.

• Adamas Reports Fourth Quarter and Full Year 2019 Financial Results

  2/25/2020

  Full year 2019 GOCOVRI® product sales of $54.6 million, a 60% increase over 2018; total paid prescriptions grew approximately 66% to 25,780

• Adamas to Present at Upcoming Healthcare Conferences - Feb. 20, 2020

  2/20/2020

  Adamas Pharmaceuticals, Inc. announced that Neil F. McFarlane, the Company’s Chief Executive Officer, is scheduled to present at the following investor conferences

• Adamas to Announce Fourth Quarter 2019 Financial Results and Host Conference Call on February 25, 2020

  2/19/2020

  Adamas Pharmaceuticals, Inc. announced that the company will report 2019 fourth quarter financial results on Tuesday, February 25, 2020, after market close.

• 

  Clinical Catch-Up: February 10-14

  2/17/2020

  It was a very busy week for clinical trial news. Here’s a look.

• Adamas To Present Analysis of Clinical Trials on GOCOVRI® Treatment at the 3rd Pan American Parkinson’s Disease and Movement Disorders Congress

  2/13/2020

  EMERYVILLE, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurological diseases, announced today two presentations on GOCOVRI ® (amantadine) extended release capsules for the treatment of dyskinesia in people with Parkinson's disease (PD) receiving levodopa-based therapy at the 3rd Pan American Parkinson’s Disease and Movement D

• Adamas Announces Publication of the Two-Year Phase 3 Open-Label EASE LID 2 Trial of GOCOVRI® for Dyskinesia in Patients with Parkinson’s Disease

  2/11/2020

  Final results reported from the longest-running clinical trial of an amantadine product in Parkinson’s disease

• 

  Multiple Sclerosis Update: Biogen, Sanofi, Active, Adamas and Novartis

  2/6/2020

  Biogen successfully fended off a patent challenge from generic company Mylan over its multiple sclerosis (MS) drug Tecfidera.